search
Back to results

Hospital-based Diabetes Prevention Study in Korea

Primary Purpose

PreDiabetes

Status
Unknown status
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Exercise and Diet remedies
Metformin
Sponsored by
Jeong-taek Woo
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for PreDiabetes focused on measuring Diabetes Prevention

Eligibility Criteria

31 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. 30<Age<71
  2. BMI≥23 kg/m2
  3. '75g Oral glucose tolerance 2 hours after the test Blood glucose140~199mg/dL' or 'Fasting Blood Sugar 110~125 mg/dL' or 'HbA1c 5.7%~6.4%'

Exclusion Criteria:

  1. Who diagnosed with Diabetes Mellitus or Who having Drugs for Diabetes Mellitus.
  2. Type 2 Diabetes Mellitus

    • Who diagnosed with Diabetes Mellitus except for maternity period.
    • Who have had drugs for Diabetes Mellitus(hypoglycemic agent or insulin) except for maternity period.
    • Fasting Glucose≥ 126 mg/dL
    • 75g Oral glucose tolerance 2 hours after the Blood glucose ≥ 200 mg/dL
    • HbA1c ≥ 6.5%
  3. Who life expectancy is short.

    • Cardiac history

      • History of severe cardiovascular disease within the last 6 months (cerebral hemorrhage, stroke, myocardial infarction, angina pectoris, heart failure, etc.)
      • Systolic blood pressure >180 mmHg or Diastolic blood pressure >105 mmHg
      • aortic stenosis
      • Left bundle branch block or Third degree AV block
    • Who had been diagnosed and treated for malignant tumors including leukemia and lymphoma within the last 5 years
    • Abnormal renal function (Creatinine ≥ 1.4 mg/dL (male) or ≥ 1.3 mg/dL (female) or Urine Protein ≥ 2 +)
    • Anemia(Hematocrit <36%((male) or><33%(female)) ⑤ Cirrhosis or chronic active hepatitis (AST/ALT>3UNL)
    • Acute gastrointestinal disease (pancreatitis, infectious intestinal disease)
    • Who is scheduled major surgery within the last 3 to 6 months or just after the surgery.
    • Chronic infection (HIV, active tuberculosis, etc.)
    • Pulmonary patients who rely on oxygen or daily bronchodilators
  4. Who is judged to be able to influence the clinical trial by investigator.

    • Who can not communicate
    • Those with psychiatric or cognitive impairment that may affect the compliance of the clinical trial
    • Those who do not agree to the treatment group allocation by random assignment
    • Those who participate in other studies that may interfere with the clinical trial
    • Those who lost weight by more than 10% during the past 6 months, excluding weight loss after giving birth
    • Those who can not have normal walking or exercise
    • Women who are pregnant
    • Those who are currently pregnant or who are within the last 3 months after giving birth
    • Those planning pregnancy during the clinical trial period
    • Those who have a history of drug and alcohol abuse (acute, chronic) within the last 2 years
    • Those who are not appropriate or unreliable for clinical trials at the discretion of the tester
  5. Who taking medication or medical condition that may affect the diagnosis of diabetes

    • Thiazide diuretics
    • Systemic beta blockers
    • Taking Niacin for the treatment of neutropenic depression
    • Possibility of taking or injecting a systemic steroid preparation
    • Taking a serotonin reuptake inhibitor (SSRI) for weight loss purpose.
    • Taking medicine for weight loss
    • Hormone status is not appropriate during thyroid hormone replacement therapy (TSH abnormal range) (If thyroid hormone therapy is stable for more than 3 months and TSH is normal, the patient can participate in)
    • Others with other endocrine diseases (eg Cushing's syndrome, acromegaly)
    • During treatment, fasting plasma triglyceride> 600 mg / dL

Sites / Locations

  • Kyunghee University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Experimental

Active Comparator

Arm Label

Conventional Management

Life style modification

Metformin

Arm Description

A patient will receive 30 minutes of individual education from the investigator, based on the standard guidelines of the Korean Diabetes Association. And will be followed up every 6 months for 36 months.

Proceed according to the Intervention Protocol developed by the Nutrition Committee of the Korean Diabetes Association. Aim to lose more than 5% of weight within 6 months, and then aim to keep weight loss constantly. After randomization, the diabetes educator team (physician / nurse / dietician) applies the intervention program for exercise therapy and diet therapy, and manages it through online education (telephone visit) and offline education (institution visit). Exercise: Moderate or abnormal exercise for more than 150 minutes per week (moderate or abnormal exercise for 30 minutes or more per day) Diet remedies: Train Calorie intake, nutrient intake and Monitoring.

After randomization, take 250 mg once a day for 2 weeks. If there is no side effect, take 500 mg once a day for 2 weeks. If there are no side effects, the maximum dose can be increased to 1000mg.

Outcomes

Primary Outcome Measures

Cumulative incidence of Diabetes Mellitus after randomization
Definition of "incidence of Diabetes Mellitus" Fasting Glucose ≥126 mg/dL or 75g Oral glucose tolerance test 2 hours after the Blood glucose ≥ 200 mg / dL or HbA1c≥6.5%

Secondary Outcome Measures

Change on HbA1c
Change on Fasting Glucose
Change on HOMA2%S
Change on HOMA2%B

Full Information

First Posted
November 28, 2016
Last Updated
July 21, 2017
Sponsor
Jeong-taek Woo
Collaborators
National Evidence-Based Healthcare Collaborating Agency, Kyungpook National University Hospital, Korea University Guro Hospital, Pusan National University Hospital, Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, Ajou University School of Medicine, Severance Hospital, Chonbuk National University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02981121
Brief Title
Hospital-based Diabetes Prevention Study in Korea
Official Title
Hospital-based Diabetes Prevention Study in Korea: A Prospective, Multi-center, Randomized, Open-label Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Unknown status
Study Start Date
November 2016 (undefined)
Primary Completion Date
November 2019 (Anticipated)
Study Completion Date
November 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jeong-taek Woo
Collaborators
National Evidence-Based Healthcare Collaborating Agency, Kyungpook National University Hospital, Korea University Guro Hospital, Pusan National University Hospital, Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, Ajou University School of Medicine, Severance Hospital, Chonbuk National University Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators will study prevention effect of Life style modification on diabetes mellitus comparing with conventional management and Metformin administration.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PreDiabetes
Keywords
Diabetes Prevention

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
744 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Conventional Management
Arm Type
No Intervention
Arm Description
A patient will receive 30 minutes of individual education from the investigator, based on the standard guidelines of the Korean Diabetes Association. And will be followed up every 6 months for 36 months.
Arm Title
Life style modification
Arm Type
Experimental
Arm Description
Proceed according to the Intervention Protocol developed by the Nutrition Committee of the Korean Diabetes Association. Aim to lose more than 5% of weight within 6 months, and then aim to keep weight loss constantly. After randomization, the diabetes educator team (physician / nurse / dietician) applies the intervention program for exercise therapy and diet therapy, and manages it through online education (telephone visit) and offline education (institution visit). Exercise: Moderate or abnormal exercise for more than 150 minutes per week (moderate or abnormal exercise for 30 minutes or more per day) Diet remedies: Train Calorie intake, nutrient intake and Monitoring.
Arm Title
Metformin
Arm Type
Active Comparator
Arm Description
After randomization, take 250 mg once a day for 2 weeks. If there is no side effect, take 500 mg once a day for 2 weeks. If there are no side effects, the maximum dose can be increased to 1000mg.
Intervention Type
Behavioral
Intervention Name(s)
Exercise and Diet remedies
Intervention Type
Drug
Intervention Name(s)
Metformin
Primary Outcome Measure Information:
Title
Cumulative incidence of Diabetes Mellitus after randomization
Description
Definition of "incidence of Diabetes Mellitus" Fasting Glucose ≥126 mg/dL or 75g Oral glucose tolerance test 2 hours after the Blood glucose ≥ 200 mg / dL or HbA1c≥6.5%
Time Frame
36 months from the baseline
Secondary Outcome Measure Information:
Title
Change on HbA1c
Time Frame
12, 24, 36 months from the baseline
Title
Change on Fasting Glucose
Time Frame
12, 24, 36 months from the baseline
Title
Change on HOMA2%S
Time Frame
12, 24, 36 months from the baseline
Title
Change on HOMA2%B
Time Frame
12, 24, 36 months from the baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
31 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 30<Age<71 BMI≥23 kg/m2 '75g Oral glucose tolerance 2 hours after the test Blood glucose140~199mg/dL' or 'Fasting Blood Sugar 110~125 mg/dL' or 'HbA1c 5.7%~6.4%' Exclusion Criteria: Who diagnosed with Diabetes Mellitus or Who having Drugs for Diabetes Mellitus. Type 2 Diabetes Mellitus Who diagnosed with Diabetes Mellitus except for maternity period. Who have had drugs for Diabetes Mellitus(hypoglycemic agent or insulin) except for maternity period. Fasting Glucose≥ 126 mg/dL 75g Oral glucose tolerance 2 hours after the Blood glucose ≥ 200 mg/dL HbA1c ≥ 6.5% Who life expectancy is short. Cardiac history History of severe cardiovascular disease within the last 6 months (cerebral hemorrhage, stroke, myocardial infarction, angina pectoris, heart failure, etc.) Systolic blood pressure >180 mmHg or Diastolic blood pressure >105 mmHg aortic stenosis Left bundle branch block or Third degree AV block Who had been diagnosed and treated for malignant tumors including leukemia and lymphoma within the last 5 years Abnormal renal function (Creatinine ≥ 1.4 mg/dL (male) or ≥ 1.3 mg/dL (female) or Urine Protein ≥ 2 +) Anemia(Hematocrit <36%((male) or><33%(female)) ⑤ Cirrhosis or chronic active hepatitis (AST/ALT>3UNL) Acute gastrointestinal disease (pancreatitis, infectious intestinal disease) Who is scheduled major surgery within the last 3 to 6 months or just after the surgery. Chronic infection (HIV, active tuberculosis, etc.) Pulmonary patients who rely on oxygen or daily bronchodilators Who is judged to be able to influence the clinical trial by investigator. Who can not communicate Those with psychiatric or cognitive impairment that may affect the compliance of the clinical trial Those who do not agree to the treatment group allocation by random assignment Those who participate in other studies that may interfere with the clinical trial Those who lost weight by more than 10% during the past 6 months, excluding weight loss after giving birth Those who can not have normal walking or exercise Women who are pregnant Those who are currently pregnant or who are within the last 3 months after giving birth Those planning pregnancy during the clinical trial period Those who have a history of drug and alcohol abuse (acute, chronic) within the last 2 years Those who are not appropriate or unreliable for clinical trials at the discretion of the tester Who taking medication or medical condition that may affect the diagnosis of diabetes Thiazide diuretics Systemic beta blockers Taking Niacin for the treatment of neutropenic depression Possibility of taking or injecting a systemic steroid preparation Taking a serotonin reuptake inhibitor (SSRI) for weight loss purpose. Taking medicine for weight loss Hormone status is not appropriate during thyroid hormone replacement therapy (TSH abnormal range) (If thyroid hormone therapy is stable for more than 3 months and TSH is normal, the patient can participate in) Others with other endocrine diseases (eg Cushing's syndrome, acromegaly) During treatment, fasting plasma triglyceride> 600 mg / dL
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jeong-Taek Woo
Phone
822-958-8220
Email
jtwoomd@khmc.or.kr
First Name & Middle Initial & Last Name or Official Title & Degree
Sang Youl Rhee
Phone
822-958-8220
Email
bard95@hanmail.net
Facility Information:
Facility Name
Kyunghee University Medical Center
City
Seoul
ZIP/Postal Code
02447
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeong-taek Woo, MD, PhD
Phone
+82-2-958-8128
Email
jtwoomd@khmc.or.kr
First Name & Middle Initial & Last Name & Degree
Sang Youl Rhee, MD, PhD
Phone
+82-2-958-8220
Email
bard95@hanmail.net
First Name & Middle Initial & Last Name & Degree
Jeong-taek Woo, MD, PhD
First Name & Middle Initial & Last Name & Degree
Suk Chon, MD, PhD
First Name & Middle Initial & Last Name & Degree
Sang Youl Rhee, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30398039
Citation
Rhee SY, Chon S, Ahn KJ, Woo JT; Korean Diabetes Prevention Study Investigators. Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study. Diabetes Metab J. 2019 Feb;43(1):49-58. doi: 10.4093/dmj.2018.0033. Epub 2018 Nov 2.
Results Reference
derived

Learn more about this trial

Hospital-based Diabetes Prevention Study in Korea

We'll reach out to this number within 24 hrs